Colorectal Cancer Mutation Panel (KRAS, PIK3CA, BRAF, NRAS)
Use
This panel detects tumor-associated somatic mutations in KRAS, NRAS, BRAF, and PIK3CA, which are oncogenes associated with colorectal cancer. Mutations in these genes—particularly in KRAS, NRAS, BRAF, and specific exons of PIK3CA—predict diminished response to EGFR-targeted therapies (e.g., cetuximab, panitumumab) and may be associated with more aggressive clinical behavior in metastatic colorectal cancer.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
0 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
4 unstained charged (+) slides
Container
Formalin‑fixed, paraffin‑embedded tissue block
Collection Instructions
For submission of paraffin block, tissue source and block ID are required on the test requisition. A pathology report must be submitted.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 5 years |
| Refrigerated | 5 years |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant